Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease

Press releaseIndivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of ...
Medical Xpress

Use of psychotropics increases in the early stages of Parkinson's disease

Up to 1 in 3 people with Parkinson's disease use at least one psychotropic medication, a recent study from the University of Eastern Finland shows. People with Parkinson's disease were using ...
Times-Standard

Ask the Doctors | Researching GLP-1 drugs, Parkinson’s progression

The results of the most recent study are disappointing. But the researchers have proposed more studies to explore similar drugs that may reach other targets in the brain. The potential for GLP-1 drugs ...
TMCnet

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson's Disease

Remepy, a pioneer in Hybrid Drugs™, today announced that the Phase IIa clinical trial of Hybridopa™, a new Hybrid Drug for Parkinson's disease, met its primary endpoint, delivering statistically ...

Gut Health Could Signal Parkinson’s Risk Years Before Symptoms, New UCL Study Finds

The gut microbiome is a ripe target for future treatments that could potentially stop or slow PD progression at an early ...